RBC Capital Maintains Outperform on Insulet, Lowers Price Target to $280

Benzinga Newsdesk www.benzinga.com Negative 95.7%

Neg 95.7% Neu 0% Pos 0%

RBC Capital analyst Shagun Singh maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $325 to $280.